Research programme: therapeutic peptides and antibodies - Amgen/Dyax

Drug Profile

Research programme: therapeutic peptides and antibodies - Amgen/Dyax

Latest Information Update: 09 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; Dyax
  • Class Antibodies; Peptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 09 Sep 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
  • 14 Jun 2007 This programme is still in active development
  • 24 Aug 2004 Preclinical trials in Undefined in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top